Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of Hib-MenAC vaccine in infants in Ghana
ISRCTN35754083Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2005
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of haemophilus type b and meningococcal group C conjugate vaccine, Tritanrix-HepB, haemophilus influenzae type b vaccine and unconjugated meningococcal polysaccharide vaccine (serogroups A, C) in meningococcal disease, Haemophilus influenzae type b disease (Hib), hepatitis B (HBV) and 3 more (2 arms), sponsored by GSK. Primary endpoints: Immunogenicity against meningococcal serogroups A and C and Non-inferiority for shared vaccine antigens. Started Jan 2005; status: completed.
02
Drugs
haemophilus type b and meningococcal group C conjugate vaccineTritanrix-HepBhaemophilus influenzae type b vaccineunconjugated meningococcal polysaccharide vaccine (serogroups A, C)
03
Conditions
meningococcal diseaseHaemophilus influenzae type b disease (Hib)hepatitis B (HBV)diphtheriaTetanus
Beyond the preview
Go deeper on ISRCTN35754083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN35754083.